KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Current Deferred Revenue (2017 - 2026)

Neogenomics filings provide 10 years of Current Deferred Revenue readings, the most recent being $899000.0 for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue fell 38.51% to $899000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $899000.0, a 38.51% decrease, with the full-year FY2025 number at $1.2 million, up 202.44% from a year prior.
  • Current Deferred Revenue hit $899000.0 in Q1 2026 for Neogenomics, down from $1.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.6 million in Q4 2022 to a low of $409000.0 in Q4 2024.
  • Median Current Deferred Revenue over the past 5 years was $1.6 million (2025), compared with a mean of $3.2 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 83.72% in 2024 and later soared 202.44% in 2025.
  • Neogenomics' Current Deferred Revenue stood at $7.6 million in 2022, then plummeted by 71.81% to $2.1 million in 2023, then tumbled by 80.8% to $409000.0 in 2024, then soared by 202.44% to $1.2 million in 2025, then decreased by 27.32% to $899000.0 in 2026.
  • The last three reported values for Current Deferred Revenue were $899000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.6 million (Q3 2025) per Business Quant data.